Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roluperidone for Negative Symptoms in Schizophrenia
NCT07565428Phase 3Recruiting
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roluperidone in schizophrenia, sponsored by Minerva Neurosciences, Inc.. Started Apr 2026; status: recruiting.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07565428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565428.